α-Blocker monotherapy and anticipated occurrences of heart failure in hypertensive veterans [2]

American Journal of Hypertension

Volumn 18, Issue 4, 2005, Pages 573-575

  Parra, David ^a   Lundy, Amber Lea ^a   Bierman, Betsy ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; CANCER INCIDENCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SOLDIER;

EID: 17044386234     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.10.007     Document Type: Letter

References (8)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
2. P. Koval, T. McDiarmid How effective is doxazosin compared with chlorthalidone in the treatment of hypertension? J Fam Prac 49 2000 597 598
3. B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright, M.A. Farber, J.V. Felicetta, J.D. Stokes ALLHAT Collaborative Research Group Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Ann Intern Med 137 2002 313 320
4. J. Meltzer A specialist in clinical hypertension critiques ALLHAT Am J Hypertens 16 2003 416 420
5. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, K.H. Flohr, S. Goldman, F.R. Cobb, P.M. Shah, R. Saunders, R.D. Fletcher, H.S. Loeb, V.C. Hughes, B. Baker Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study N Engl J Med 314 1986 1547 1552
6. R.S. Stafford, C.D. Furberg, S.N. Finkelstein, I.M. Cockburn, T. Alehegn, J. Ma Impact of clinical trial results on national trends in α-blocker prescribing. 1996-2002 JAMA 291 2004 54 62
7. Pfizer Facts: Utilization of Veterans Affairs Medical Care Services by United States Veterans. PG002133, Pfizer, Inc, May 2003. The analyses reported in this monograph were a cooperative effort between Pfizer (Population Studies Branch of Pfizer Outcomes Research, directed by Margaret McDonald, PhD) and the VA Houston Center for Quality of Care and Utilization Studies (Nancy J. Petersen, PhD, project leader).
8. P.T. Scardino The prevention of prostate cancer--the dilemma continues N Engl J Med 349 2003 297 299